ArticleScientific reports2015
Antitumor and Adjuvant Activity of λ-carrageenan by Stimulating Immune Response in Cancer Immunotherapy.
Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 116 citations in OpenAlex.
- Carrageenan: Food Additive or Health Concern? A Comprehensive Review.Annals of nutrition & metabolism · 2026Review
- Antitumoral activities of λ‑carrageenan oligosaccharide- based nanoparticles.Journal of nanobiotechnology · 2026Article
- Article
- Therapeutic investigation of Jania rubens polysaccharides: antimicrobial activity and potentiation of chemotherapy in colorectal cancer cells.BMC complementary medicine and therapies · 2026Article
- Role of Main Red Seaweed Bioactive Compounds in Modulating Redox Imbalance and Cholinergic Dysfunction: Insights from In Vitro Assays.Current issues in molecular biology · 2026Review
- Prebiotic and Functional Fibers from Micro- and Macroalgae: Gut Microbiota Modulation, Health Benefits, and Food Applications.International journal of molecular sciences · 2025Review
- Carrageenan: structure, properties and applications with special emphasis on food science.RSC advances · 2025Review
- Sustainable and biocompatible hybrid materials-based sulfated polysaccharides for biomedical applications: a review.RSC advances · 2025Review
- Traditional Chinese medicine as potential adjuvants for tumor vaccines: a review of types, mechanisms, and forms.Frontiers in immunology · 2025Review
- Recent biotechnological applications of value-added bioactive compounds from microalgae and seaweeds.Botanical studies · 2024Review
- Review
- Marine-derived κ-carrageenan-coated zinc oxide nanoparticles for targeted drug delivery and apoptosis induction in oral cancer.Molecular biology reports · 2024Article
- Acute remote ischemic conditioning enhances (CD3+)- but not (FoxP3+)-T-cell invasion in the tumor center and increases IL 17 and TNF-alpha expression in a murine melanoma model.Frontiers in immunology · 2024Article
- Nanotechnology-driven improvisation of red algae-derived carrageenan for industrial and bio-medical applications.World journal of microbiology & biotechnology · 2023Review
- Natural-Product-Derived Adjunctive Treatments to Conventional Therapy and Their Immunoregulatory Activities in Triple-Negative Breast Cancer.Molecules (Basel, Switzerland) · 2023Review
- Polysaccharides-Naturally Occurring Immune Modulators.Polymers · 2023Review
- Article
- Carrageenans and Their Oligosaccharides from Red SeaweedsInternational journal of molecular sciences · 2023Article
- Review
- Beneficial effects of seaweed-derived components on metabolic syndrome via gut microbiota modulation.Frontiers in nutrition · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
λ-Carrageenan is a seaweed polysaccharide which has been generally used as proinflammatory agent in the basic research, however, how the immunomodulating activity of λ-carrageenan affects tumor microenvironment remains unknown. In this study, we found that intratumoral injection of λ-carrageenan could inhibit tumor growth in B16-F10 and 4T1 bearing mice and enhance tumor immune response by increasing the number of tumor-infiltrating M1 macrophages, DCs and more activated CD4(+)CD8(+) T lymphocytes in spleen. In addition, λ-carrageenan could enhance the secretion of IL17A in spleen and significantly increase the level of TNF-α in tumor, most of which was secreted by infiltrating macrophages. Moreover, λ-carrageenan exhibited an efficient adjuvant effect in OVA-based preventative and therapeutic vaccine for cancer treatment, which significantly enhanced the production of anti-OVA antibody. The toxicity analysis suggested that λ-carrageenan was with a good safety profile. Thus, λ-carrageenan might be used both as a potent antitumor agent and an efficient adjuvant in cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.